NCT06750484 2026-02-27
Trial of Trastuzumab Deruxtecan in Previously Treated HER2
Yale University
Phase 2 Recruiting
Clinical Trials
15 trialsNCT06849947 2025-12-24
Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer
Samsung Medical Center
Phase 2 Not yet recruiting
NCT04603183 2025-12-12
ABIGAIL
MedSIR
Phase 2 Completed
NCT06876636 2025-07-29
Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer
Xijing Hospital
Phase NA Active not recruiting
NCT03328884 2025-04-23
Phenomenal
MedSIR
Phase 2 Completed
NCT06611891 2025-03-04
DOTABREAST
University Hospital, Grenoble
Phase 3 Recruiting
NCT06857305 2025-03-04
Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Enrolling by invitation
NCT06718933 2025-02-06
Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis
Fudan University
Phase 1/2 Recruiting
NCT06298084 2024-03-29
ICARUSBREAST02
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT03322215 2024-03-08
PASIPHAE
Karolinska University Hospital
Phase 2 Terminated
NCT05759546 2024-02-06
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT05759572 2024-02-06
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
Fudan University
Phase 2 Recruiting
NCT03555877 2023-07-07
AMICA
GBG Forschungs GmbH
Phase 2 Completed
NCT02511639 2020-12-03
MAIN-A
Istituto Oncologico Veneto IRCCS
Phase 3 Completed
NCT03086785 2018-01-17
Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2 Unknown